# Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer

> **NCT02674568** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 342 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Rovalpituzumab tesirine

## Key facts

- **NCT ID:** NCT02674568
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-25
- **Primary completion:** 2018-10-19
- **Final completion:** 2018-10-19
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02674568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02674568, "Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02674568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*